Conflict of Interest
Tomas, P., Johnson & Johnson, and Pfizer., Janssen R&D
FOUNDER
Charu Aggarwal reported receiving institutional research funding from AstraZeneca, Genentech, Incyte, Macrogenics, Medimmune, and Merck Sharp & Dohme, and receiving consultation fees from Genentech, Lilly, Celgene Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/AstraZeneca, Regeneron/Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen, and Boehringer Ingelheim. Joshua M. Bauml is currently employed by Janssen R&D, but all work for this study was done as an employee at University of Pennsylvania. Lova Sun reported clinical trial funding (to institution) from Blueprint, Seagen, and IO Biotech, and honoraria/advisory board member for Regeneron, GenMab, Seagen, and MJH Life Sciences. Melina E. Marmarelis reported researching funding (to institution) from Eli Lilly, AstraZeneca, Merck, and Genentech, a consulting role with AstraZeneca, Novocure, Boehringer Ingelheim, Janssen, Takeda, Blueprint Pharmaceuticals, Bristol Myers Squibb, and Ikena, and honorarium from Thermo Fisher, and stock in Gilead Sciences, Portola Pharmaceuticals, Merck, Bluebird Bio, Johnson & Johnson, and Pfizer. Corey J. Langer reported grants from Eli Lilly, Trizell, Merck, Takeda, Inovio, AstraZeneca, Oncocyte, and Boehringer Ingelheim; consulting fees from Boehringer Ingelheim, Novocure, Takeda, Genentech/Roche, AstraZeneca, Merck, Gilead, GSK, Pfizer, Regeneron, Mirati, Sanofi-Aventis, and Heat Biologics; medical writing for Novartis, and DSMB co-chair for Amgen, OncocyteDX, and Veterans Administration. Ravi Amaravadi reported a consulting relationship with Deciphera and Tasca, research funding from Novartis, BMS, Pfizer, and Deciphera, and Scientific Founder of Pinpoint Therapeutics. Alisha P. Maity, Qi Long, Tomas Aleman, Christine Ciunci, Christopher D’ Avella, Melissa Volpe, Evan Anderson, Lisa McCormick Jones, Aditi P. Singh, and Roger B. Cohen indicated no financial relationships.